These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23468127)

  • 21. Gender Differences in Patients with Prolactinoma: Single-center Ukrainian Experience.
    Voznyak O; Zinkevych I; Lytvynenko A; Hryniv N; Ilyuk R; Kobyliak N
    Rev Recent Clin Trials; 2024; 19(3):204-214. PubMed ID: 38561622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mean platelet volume in patients with prolactinoma.
    Tam AA; Kaya C; Başer H; Ersoy R; Çakır B
    Arch Endocrinol Metab; 2016 Aug; 60(4):319-22. PubMed ID: 26886093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery.
    Zielinski G; Ozdarski M; Maksymowicz M; Szamotulska K; Witek P
    Front Endocrinol (Lausanne); 2020; 11():439. PubMed ID: 32733387
    [No Abstract]   [Full Text] [Related]  

  • 25. Macroprolactinemia in patients with prolactinomas: prevalence and clinical significance.
    Elenkova A; Genov N; Abadzhieva Z; Kirilov G; Vasilev V; Kalinov K; Zacharieva S
    Exp Clin Endocrinol Diabetes; 2013 Apr; 121(4):201-5. PubMed ID: 23595795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolactin, prolactin disorders, and dopamine agonists during pregnancy.
    Levin G; Rottenstreich A
    Hormones (Athens); 2019 Jun; 18(2):137-139. PubMed ID: 30341577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses.
    Araújo C; Marques O; Almeida R; Santos MJ
    Endocrine; 2018 Nov; 62(2):470-476. PubMed ID: 30088141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
    Eroukhmanoff J; Tejedor I; Potorac I; Cuny T; Bonneville JF; Dufour H; Weryha G; Beckers A; Touraine P; Brue T; Castinetti F
    Eur J Endocrinol; 2017 Mar; 176(3):323-328. PubMed ID: 28073906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
    Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
    Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aromatase inhibitors as a therapeutic strategy for male prolactinoma resistant to dopamine agonists: a retrospective cohort study and literature review.
    Zúñiga D; Stumpf MAM; Monteiro ALS; Glezer A
    J Endocrinol Invest; 2024 May; 47(5):1295-1303. PubMed ID: 37938428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gender-related differences in prolactin secretion in pituitary prolactinomas.
    Nishioka H; Haraoka J; Akada K; Azuma S
    Neuroradiology; 2002 May; 44(5):407-10. PubMed ID: 12012125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
    Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
    Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
    Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative treatment with dopamine agonist therapy influences surgical outcome in prolactinoma: a retrospective single-center on 159 patients.
    Ryba A; Gonzalez Lopez D; Rotermund R; Flitsch J
    Acta Neurochir (Wien); 2024 Aug; 166(1):316. PubMed ID: 39085706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term Follow-up of 84 Patients With Giant Prolactinomas-A Swedish Nationwide Study.
    Himonakos C; Burman P; Borg H; Dahlqvist P; Engström BE; Ekman B; Emilsson L; Olsson DS; Ragnarsson O; Wahlberg J; Åkerman AK; Höybye C; Berinder K
    J Clin Endocrinol Metab; 2023 Nov; 108(12):e1506-e1514. PubMed ID: 37403202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of the Leksell gamma knife in the treatment of prolactinoma patients.
    Jezková J; Hána V; Krsek M; Weiss V; Vladyka V; Liscák R; Vymazal J; Pecen L; Marek J
    Clin Endocrinol (Oxf); 2009 May; 70(5):732-41. PubMed ID: 18710463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA.
    Choudhary C; Hamrahian AH; Bena JF; Recinos P; Kennedy L; Dobri G
    Endocr Pract; 2019 Jul; 25(7):684-688. PubMed ID: 30865525
    [No Abstract]   [Full Text] [Related]  

  • 40. Predictors of the Response to Dopaminergic Therapy in Patients With Prolactinoma.
    Hage C; Salvatori R
    J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32930718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.